Inotek Pharma - Company & Market Research Reports

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts. It is focused on the development and commercialization of therapies for glaucoma and other serious diseases of the eye. The company's lead product candidate is Trabodenoson, formerly known as INO-8875, which is in Phase III clinical trials for lowering IOP. Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG. Inotek was founded in 1999.

Global Glaucoma Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025 - Product Thumbnail Image

Global Glaucoma Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • Report
From
Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026 - Product Thumbnail Image

Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026

  • Report
  • 228 Pages
From
Global Glaucoma treatment Market Research and Forecast 2018-2023 - Product Thumbnail Image

Global Glaucoma treatment Market Research and Forecast 2018-2023

  • Report
From
Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market - Product Thumbnail Image

Global Glaucoma Treatment Drugs Market Forecast to 2020 - New Product Launches Expected to Boost Market

  • Report
  • 150 Pages
From
Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview  - Product Thumbnail Image

Ocular Disorders: Rising Therapeutics, Technologies, and Devices - Overview

  • Report
  • 208 Pages
From
Open-Angle Glaucoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Open-Angle Glaucoma - Pipeline Review, H2 2016

  • Drug Pipelines
  • 123 Pages
From
Open-Angle Glaucoma - Pipeline Review, H1 2016 - Product Thumbnail Image

Open-Angle Glaucoma - Pipeline Review, H1 2016

  • Drug Pipelines
  • 121 Pages
From
Optic Neuropathy Global Clinical Trials Review, H1, 2018 - Product Thumbnail Image

Optic Neuropathy Global Clinical Trials Review, H1, 2018

  • Clinical Trials
  • 59 Pages
From
Open-Angle Glaucoma - Pipeline Review, H2 2015 - Product Thumbnail Image

Open-Angle Glaucoma - Pipeline Review, H2 2015

  • Drug Pipelines
  • 94 Pages
From
Open-Angle Glaucoma - Pipeline Review, H1 2015 - Product Thumbnail Image

Open-Angle Glaucoma - Pipeline Review, H1 2015

  • Drug Pipelines
  • 86 Pages
From
DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026 - Product Thumbnail Image

DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026

  • Report
  • 284 Pages
From
Adenosine A1 Receptor Agonist -Pipeline Insight, 2018 - Product Thumbnail Image

Adenosine A1 Receptor Agonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Adenosine A2A Receptor Agonist -Pipeline Insight, 2018 - Product Thumbnail Image

Adenosine A2A Receptor Agonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Adenosine A3 Receptor Agonist -Pipeline Insight, 2018 - Product Thumbnail Image

Adenosine A3 Receptor Agonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Glaucoma Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Glaucoma Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 586 Pages
From
Retinal Degeneration Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

Retinal Degeneration Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • 73 Pages
From
Adenosine A1 Receptor Antagonist -Pipeline Insight, 2018 - Product Thumbnail Image

Adenosine A1 Receptor Antagonist -Pipeline Insight, 2018

  • Drug Pipelines
  • 60 Pages
From
Contrast Induced Nephropathy Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Contrast Induced Nephropathy Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 108 Pages
From
Cancer Therapies - Global Strategic Business Report - Product Thumbnail Image

Cancer Therapies - Global Strategic Business Report

  • Report
  • 897 Pages
From
Competitor Analysis - Antibody Therapy of Inflammatory and Autoimmune Diseases - Product Thumbnail Image

Competitor Analysis - Antibody Therapy of Inflammatory and Autoimmune Diseases

  • Report
  • 172 Pages
From
Loading Indicator
adroll